*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Asymchem Laboratories (Tianjin) Co., Ltd.**
**凱萊英醫藥集團(天津)股份有限公司**
*(A joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock Code: 6821)**

# ADJUSTMENT TO THE REPURCHASE PRICE UNDER THE RESTRICTED 2025 A SHARE SCHEME

Reference is made to the announcements of Asymchem Laboratories (Tianjin) Co., Ltd. (the "**Company**") dated 24 January 2025, 3 April 2025 and 29 September 2025, and the circular of the Company dated 18 March 2025, in relation to, among others, the 2025 A share restricted share incentive scheme of the Company (the "**2025 A Share Scheme**") and the grant of restricted A Shares thereunder, and announcements of the Company dated 28 March 2025 and 18 June 2025, and the circular of the Company dated 19 May 2025, in relation to, among others, the 2024 Profit Distribution Plan (collectively, the "**Announcements and Circulars**"). Unless otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements and Circulars.

## I. ADJUSTMENT TO THE REPURCHASE PRICE

On 11 June 2025, the Company held the 2024 annual general meeting, at which the proposed 2024 profit distribution plan of the Company (the "**2024 Profit Distribution Plan**") was considered and approved. Pursuant to the 2024 Profit Distribution Plan, the Company distributed a cash dividend of RMB11.00 (tax inclusive) for every 10 shares to the shareholders based on the total share capital of the Company as at the record date for profit distribution.

Pursuant to the relevant provisions of the 2025 A Share Scheme, if there is any capitalisation issue, bonus issue, stock split, rights issue or share consolidation, dividends and other matters of the Company affecting the total share capital or the share price of the Company after the completion of the registration of the restricted A Shares granted to the participants, the Company shall make adjustment (the "**Adjustment**") to the repurchase price of the restricted A Shares for first grants yet to be unlocked (the "**Repurchase Price**") accordingly. Details of the Adjustment are as follows:

$P = P_0 - V = RMB37.52 - RMB1.1 = RMB36.42$ per share

Where: P represents the Repurchase Price after Adjustment; V represents the amount of dividend per share; $P_0$ represents the Grant Price.

Based on the aforesaid, the Repurchase Price for first grants under the 2025 A Share Scheme was adjusted from RMB37.52 per share to RMB36.42 per share.

## II. IMPACT OF THE ADJUSTMENT ON THE COMPANY

The Adjustment will not have any material impact on the financial position and operating results of the Company.

## III. OPINION OF THE REMUNERATION AND EXAMINATION COMMITTEE

The Remuneration and Examination Committee is of the view that in light of the 2024 Profit Distribution Plan having been completed and in compliance with the relevant laws, regulations and rules such as the Administrative Measures for the Equity Incentives of Listed Companies (《上市公司股權激勵管理辦法》) (the "**Administrative Measures**") and the 2025 A Share Scheme, the Company shall adjust the Repurchase Price for the initial grant under the 2025 A Share Scheme. The Remuneration and Examination Committee agreed to the Adjustment, adjusting the Repurchase Price for the initial grant under the 2025 A Share Scheme from RMB37.52 per share to RMB36.42 per share.

## IV. LEGAL OPINION FROM THE PRC LEGAL ADVISOR OF THE COMPANY

DeHeng Law Offices, the PRC legal advisor of the Company, are of the view that, as of the date of the issuance of their legal opinions, the Company has completed all necessary legal procedures required at this stage in connection with the Adjustment, and is in compliance with the Administrative Measures, the Self-Regulatory Guidelines No. 1 for the Companies Listed on the Shenzhen Stock Exchange – Business Handling (《深圳證券交易所上市公司自律監管指南第1號－ 業務辦理》) and the relevant provisions of the 2025 A Share Scheme.

By order of the Board
**Asymchem Laboratories (Tianjin) Co., Ltd.**
**Dr. Hao Hong**
*Chairperson of the Board, Executive Director and Chief Executive Officer*

Tianjin, the PRC, 19 December 2025

*As of the date of this announcement, the Board of Directors of the Company comprises Dr. Hao Hong as the Chairperson of the Board of Directors and executive Director, Ms. Yang Rui, Mr. Zhang Da and Mr. Hong Liang as executive Directors, Dr. Ye Song and Ms. Zhang Ting as non- executive Directors, and Dr. Sun Xuejiao, Dr. Hou Xinyi and Mr. Xie Weikai as independent non-executive Directors.*